Cardiotoxicity of cytotoxic drugs

Cancer Treatment Reviews

Volumn 30, Issue 2, 2004, Pages 181-191

  Schimmel, Kirsten J M ^a   Richel, Dick J ^a   van den Brink, Renée B A ^a   Guchelaar, Henk Jan ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Cardiotoxicity; Chemotherapy; Cytotoxic drugs

Indexed keywords

1 (4,5 DIHYDROXY 3 HYDROXYMETHYL 2 CYCLOPENTEN 1 YL)CYTOSINE; ANTHRACYCLINE DERIVATIVE; ANTIOXIDANT; BUSULFAN; CAPECITABINE; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; FLUOROURACIL; GLUTATHIONE PEROXIDASE; IFOSFAMIDE; MELPHALAN; MEVINOLIN; MITOMYCIN; MITOXANTRONE; PACLITAXEL; PROBUCOL; RALTITREXED; RAZOXANE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; SABARUBICIN; TRASTUZUMAB; UNINDEXED DRUG; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL; CARDIOTONIC AGENT; CHELATING AGENT; MONOCLONAL ANTIBODY;

ACUTE TOXICITY; ANGINA PECTORIS; ANTIGEN PRESENTING CELL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATRIOVENTRICULAR BLOCK; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; BRADYCARDIA; BREAST CANCER; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CHRONIC TOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY THROMBOSIS; DERMATITIS; DIAPHORESIS; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ECG ABNORMALITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART BUNDLE BRANCH BLOCK; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPOMAGNESEMIA; HYPOTENSION; IMMUNOREACTIVITY; INCIDENCE; ISCHEMIA; LEUKOPENIA; MORBIDITY; MUCOSA INFLAMMATION; MYOCARDIAL DISEASE; MYOCARDITIS; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PERICARDITIS; QT PROLONGATION; REVIEW; SIDE EFFECT; SUDDEN DEATH; TACHYCARDIA; TESTIS CANCER; THORAX PAIN; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VASOSPASM; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART; RISK FACTOR;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BIOLOGICAL MARKERS; CALCIUM CHANNELS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CHELATING AGENTS; CISPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; HEART; HUMANS; IFOSFAMIDE; OXIDATIVE STRESS; RAZOXANE; RISK FACTORS;

EID: 1642617697     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2003.07.003     Document Type: Article

References (92)

1. Meinardi MT, Gietema JA, Veldhuisen DJ van, Graaf WT van der, Vries EGE, Steijfer DT. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev 2000;26:429-47.
2. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25(Suppl 10):72-85.
3. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki L. Acute doxorubicin cardiotoxicity involves cardiomyocite apoptosis. Cancer Res 2000;60:1789-92.
4. Hatch GM, McClarty G. Regulation of cardiolipin biosynthesis in H9c2 cardiac myoblasts by cytidine 5′-triphosphate. J Biol Chem 1996;271:25810-6.
5. Lipp. Cardiotoxicity of cytotoxic drugs. Anticancer drug toxicity. Prevention, management and clinical pharmacokinetics. New York: Marcel Dekker; 1999. p. 471-488.
6. Gennari A, Salvadori B, Donati S, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 1999;17:3596-602.
7. Lieutaud T, Brain E, Golgran-Toledano, Vincent F, Cvitkovic E, Leclercq B, Escudier B. 5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? Eur J Canc 1996;32a:368-9.
8. Cwikiel M, Persson SU, Larsson H, Albertsson M, Eskilsson J. Changes of blood viscosity in patients treated with 5-fluorouracil. A link to cardiotoxicity? Acta Oncol 1995;34:83-5.
9. Wojtacki J, Lewicka-Nowack E, Lesniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention - review of the literature. Med Sci Monit 2000;6:411-20.
10. Hochster H, Wasserheit C, Speyer J. Cardiotoxicity and cardioprotection during chemotherapy. Curr Opin Oncol 1995;7:304-9.
11. Steinhertz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after competing anthracycline therapy. JAMA 1991;266:1672-7.
12. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention. Drug Safety 2000;22(4):263-302.
13. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
14. Swain M, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003;97:2869-79.
15. Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Canc Res 1992;52:194-201.
16. Launchbury AP, Habboubi N. Epirubicin and dxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treatment 1993;Rev 19:197-228.
17. Coukell A, Faulds D. Epirubicin - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of breast cancer. Drugs 1997;53:453-82.
18. Cirillo R, Sacco G, Venturella S, Brightwell J, Giachetti A, Manzini S. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. J Cardiovasc Pharmacol 2000;35:100-8.
19. Graaf H, de Dolsma WV, Willemse PHB, et al. Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. Br J Canc 1997;76:943-5.
20. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin-T in pediatric patients at risk for myocardial injury. Circulation 1997;96:2641-8.
21. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Safety 2002;25:301-11.
22. Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998;136:362-3.
23. Nousiainen T, Jantunen E, Vanninen E, et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999;62:135-41.
24. Rossi F, Fillippelli W, Russo S, Fillippellie A, Berrino L. Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharm Tox 1994;75:99-107.
25. Vasquez-Vivar J, Martasek P, Hogg N, et al. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochem 1997;36:11293-7.
26. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 1988;48:4766-9.
27. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J Clin Invest 1980;65:128-35.
28. Li T, Singal PK. Adriamycin induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 2000;102:2105-10.
29. Kotamraju S, Konorev EA, Joseph J, Kalylanaraman. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. J Biol Chem 2000;43:33585-92.
30. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999;84:257-65.
31. Guchelaar HJ, Vermes I, Koopmans RP, Reutelingperger CH. Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluororuacil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol 1998;42:77-83.
32. Minotti G, Mancusco C, Frustaci A, et al. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. J Clin Invest 1996;98:650-61.
33. Minotti G, Recalcati S, Mordente A, et al. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 1998;12:541-52.
34. Zhou S, Starkov A, Frober MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 2001;61: 771-7.
35. Shadle SE, Bammel BP, Cuack BJ, et al. Daunorubicin cardiotoxicity. Biochem Pharm 2000;60:1435-44.
36. Lampidis TJ, Krishan A, Planas L, Tapiero H. Reversal of intrinsic resistance to Adriamycin in normal cells by verapamil. Cancer Drug Delivery 1986;3:251-9.
37. Santostasi G, Kutty RK, Krishna G. Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes. Toxicol Appl Pharmacol 1991;108:140-9.
38. Akimoto H, Bruno NA, Slate DL, Billingham ME, Torti SV, Torti FM. Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes. Canc Res 1993;53:4658-64.
39. Ito H, Shimojo T, Fujisaki H, Tarnamori M, Ishiyama S, Adachi S, Abe S, Marumo F, Hiroe M. Thermal preconditioning protects rat cardiac muscle cells from doxorubicin induced apoptosis. Life Sciences 1999;64:755-61.
40. Huber SA. Doxorubicin-induced alterations incultured myocardial cells stimulate cytolytic T-lymphocyte responses. Am J Pathol 1990;137:449-56.
41. Zhang J, Herman EH, Ferrans VJ. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187. Am J Pathol 1993;142:1916-26.
42. Dorr R. Chemoprotectants for cancer chemotherapy. Semin Oncol 1991;18:48-58.
43. Myers CE, Bonow R, Palmeri S, et al. A randomised controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983;10(Suppl 1):53-5.
44. Lissoni P, Barni S, Mandala M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Canc 1999;35:1688-92.
45. Links M, Lewis C. Chemoprotectants. A review of their clinical pharmacology and therapeutic efficacy. Drugs 1999;57:293-308.
46. Herman EH, Ferrans VJ. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187). Canc Res 1981;41:3436-40.
47. Swain WM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997;15:1318-32.
48. Speyer JL, Green MD, Kramer E, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988;319:745-52.
49. Wiseman LR, Spencer CM. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998;56:385-403.
50. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996;14:362-72.
51. Hensley ML, Schuchter LM, Lindley C, et al. American Society of clinical oncology Clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333-55.
52. Hochster H, Liabes L, Wadler S, et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed dose doxorubicin. J Natl Cancer Inst 1992;84:1725-30.
53. Basser RL, Sobol MM, Duggan G, et al. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J Clin Oncol 1994;12:1659-66.
54. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996;14:3112-20.
55. Acker FAA, Boven E, Kramer K, Haenen GRMM, Bast A, Vijgh WJF. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity. Clin Cancer Res 2001;7:1378-84.
56. Iliskovic N, Singal PK. Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am J Pathol 1997;150:727-34.
57. Siveski-Iliskovic, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumour effect. Circulation 1995;91:10-5.
58. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, et al. Lovastatin potentiates antitumour activity and attenuates cardiotoxicity of doxorubicin in three tumour models in mice. Clin Cancer Res 2000;6:2044-52.
59. Gabizon A, Dagan A, Goren D, Barenholz, Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity. Cancer Res 1992;42:4734-9.
60. Mayer LD, Tai LCL, Ko DSC, et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 1989;49:5922-30.
61. 2. Ann Oncol 2000;11:1029-33.
62. Rowinsky EK, McGuire WP, Guarieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of paclitaxel. J Clin Oncol 1991;9:1704-12.
63. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-h infusion in combination with bolus doxorubicin in women with untreated metastic breast cancer: high antitumour efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-99.
64. Khayat D, Antoine E. Docetaxel in combination chemotherapy for metastatic breast cancer. Semin Oncol 1997;24(Suppl 13):S13-19-26.
65. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therpeutic potential. Drugs 1998;55:5-30.
66. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors. J Clin Oncol 1998;16:3483-5.
67. Bristow MR, Sageman WS, Scott RH, et al. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 1980;2:487-515.
68. Milward LK, Cosson EJ, Stokes KH, et al. Cremophor EL changes the pharmacokinetics of doxorubicin. Proc Am Assoc Cancer Res 1995;36:373 (abstract 2221).
69. Gianni L, Vigan L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997;15:1906-15.
70. Danesi R, Conte PF, Del Tacca M. Pharmacokinetic optimization of treatment schedules for anthracyclines and paclitaxel in cancer patients. Clin Phormacokin 1999;9:135-211.
71. Sparano JA. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. Semin Oncol 1999;26(3 Suppl 9):14-9.
72. Perez EA. Paclitaxel and cardiotoxicity. J Clin Oncol 1998;16:3481-2.
73. Gregory RK, Hill ME, Moore J, et al. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy. Eur J Cancer 2000;36:503-7.
74. Lück HJ, Thomssen C, duBois A, et al. Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Semin Oncol 1996;23(Suppl 1):33-6.
75. Becker K, Erckenbrecht JF, Haussinger D, Frieling. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999;57:475-84.
76. Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother 1994;28:374-8.
77. Bertolini A, Flumano M, Fusco O, et al. Acute cardiotoxicity during capecitabine treatment: a case report. Tumori 2001;87:200-6.
78. Schöber C, Parageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993;72: 2242-7.
79. Kuropkat C, Griem K, Clark J, Rodriguez ER, Hutchinson J, Taylor SG. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol 1999;22:466-70.
80. Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol 1990;1:409-14.
81. De Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil. A prospective clinical study. J Clin Oncol 1992;10:1795-801.
82. Kohne CH, Thuss-Patience P, Friedrich M, et al. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 1998;77:973-7.
83. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991;9:1215-23.
84. Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 1989;24:395-6.
85. Icli F, Karaoguz H, Dincol D, et al. Sever vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993;15:587-93.
86. Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986;105:48-51.
87. Meinardi MT, Gietema JA, Graaf WT van der, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18: 1725-32.
88. Gerl A, Clemm C, Wilmanns W. Acute cerebrovascular event after cisplatin based chemotherapy for testicular cancer. Lancet 1991;338:385-6.
89. Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Throm Res 2000;99:503-9.
90. Treish I, Schwartz R, Lindley C. Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health-Syst Pharm 2000;57:2063-76.
91. Feldman AM, Lorell BH, Reis SE. Trastuzumab in the treatment of metastatic breast cancer. Anticancer therapy versus cardiotoxicity. Circulation 2000;102:272-4.
92. Politi PM, Xie F, Dahut W, et al. Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemother Pharmacol 1995;36:513-23.